Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novo Nordisk reports phase III liraglutide results

Novo Nordisk reports phase III liraglutide results

20th August 2007

Novo Nordisk has announced the publication of the results of two 26-week phase III clinical studies of liraglutide as part of its liraglutide effect and action in diabetes (Lead) programme.

The Lead studies involve 2,132 patients and concern the treatment of diabetes patients whose condition is inadequately controlled by one or two orally-administered antidiabetics, with these individuals receiving varying doses in liraglutide as a combination treatment with a single antidiabetic.

In the Lead 1 study, patients administered with liraglutide exhibited statistically significant improvements in glucose control than those receiving rosiglitazone, while the Lead 2 study saw an improvement in HbA1c that was comparable to patients treated with glimepiride.

Mads Krogsgaard Thomsen, executive vice-president and chief science officer of Novo Nordisk, said: “The encouraging clinical results from the two new trials confirm the positive effect of liraglutide on blood glucose control, body weight and hypoglycaemia risk seen in previous studies.”

He added that these trial results have left the company confident that it is on course to receive regulatory approval for the compound partway through 2008.

In June 2007, Novo Nordisk reported that clinical studies had shown liraglutide to provide positive results when compared to insulin glargine in patients with type two diabetes.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.